138 related articles for article (PubMed ID: 21698837)
1. Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.
Leyva S; Marino LA; Alberú J; Morales-Buenrostro LE
Clin Transpl; 2010; ():369-82. PubMed ID: 21698837
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.
Leyva S; Marino-Vázquez LA; Reyes-Loaeza JA; Vega O; Uribe-Uribe N; Alberú J; Morales-Buenrostro LE
Clin Transpl; 2009; ():369-76. PubMed ID: 20524300
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
Cooper JE; Wiseman AC; Chan L
Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
[No Abstract] [Full Text] [Related]
4. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
[No Abstract] [Full Text] [Related]
5. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
Lubetzky M; Auli MJ; Walker J; Leeser D; Kapur S; Hartono C; Dadhania D
Clin Transpl; 2010; ():437-40. PubMed ID: 21696061
[No Abstract] [Full Text] [Related]
6. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2010; ():429-36. PubMed ID: 21696060
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.
Sberro-Soussan R; Zuberl J; Suberbielle-Boissel C; Legendre C
Clin Transpl; 2010; ():409-14. PubMed ID: 21696059
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
[TBL] [Abstract][Full Text] [Related]
9. Targeting alloantibody production with bortezomib: does it make more sense?
Lee I; Constantinescu S; Gillespie A; Rao S; Silva P; Birkenbach M; Leech S; Karachristos A; Daller JA; Sifontis NM
Clin Transpl; 2010; ():397-403. PubMed ID: 21696057
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
[TBL] [Abstract][Full Text] [Related]
11. 1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.
Shapiro R; Lunz J; Zeevi A; Basu A; Mapara M; Randhawa P; Tan HP; Sharma V; Humar A
Clin Transpl; 2010; ():405-7. PubMed ID: 21696058
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib for desensitization of patients on a waiting list for deceased donor kidney transplant: experience in Mexico City.
Marino-Vázquez LA; Leyva S; Alberú J; Morales-Buenrostro LE
Clin Transpl; 2010; ():363-7. PubMed ID: 21696054
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib is effective to treat acute humoral rejection after liver transplantation.
Lee CF; Eldeen FZ; Chan KM; Wu TH; Soong RS; Wu TJ; Chou HS; Lee WC
Transplant Proc; 2012 Mar; 44(2):529-31. PubMed ID: 22410063
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib rescue in refractory acute humoral rejection--report of a case.
Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
[No Abstract] [Full Text] [Related]
15. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D
Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
[TBL] [Abstract][Full Text] [Related]
16. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
17. Durability of antibody removal following proteasome inhibitor-based therapy.
Everly MJ; Terasaki PI; Trivedi HL
Transplantation; 2012 Mar; 93(6):572-7. PubMed ID: 22262128
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
Trials; 2014 Apr; 15():107. PubMed ID: 24708575
[TBL] [Abstract][Full Text] [Related]
20. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
